Bactericidal and Bacteriostatic Agents against Drug-Resistant Bacteria

Bookmark/Download	Download as PDF
Track Code	2019-SINT-68535
Categories	Pharmaceuticals
Keywords	Antibacteria Antibiotic Antibiotic Resistance Bactericidal Bacteriostatic E. faecalis Enterococcus L. monocytogenes Listeria MRSA Pharmaceuticals S. aureus Staphylococcus VRE
Public Abstract	Researchers at Purdue University have developed novel antimicrobial agents to solve the continued problem of drug-resistant bacterial strains; approximately 20,000 people die in the US every year from drug-resistant infections. These antimicrobial agents potently inhibit bacterial growth in several species, including drug-resistant strains, at concentrations as low as 0.0675 micrograms per milliliter. This family of compounds contains both bactericidal and bacteriostatic agents. Advantages: -Inhibits drug resistant bacteria strains -Kills bacteria at low concentration Potential Applications: -Antimicrobial Agent Related Publication: Potent trifluoromethoxy, trifluoromethylsulfonyl, trifluoromethylthio and pentafluorosulfanyl containing (1,3,4-oxadiazol-2-yl)benzamides against drug-resistant Gram-positive bacteria RSC Med. Chem., 2020,11, 102-110 DOI: 10.1039/C9MD00391F
People	Sintim, Herman O (Project leader) Naclerio, George
Intellectual Property	Application Date Nov 22, 2021 Type NATL-Patent Country of Filing Europe Patent Number (None) Issue Date (None) Application Date Oct 26, 2021 Type NATL-Patent Country of Filing United States Patent Number (None) Issue Date (None) Application Date Apr 24, 2020 Type PCT-Patent Country of Filing WO Patent Number (None) Issue Date (None) Application Date Apr 26, 2019 Type Provisional-Patent Country of Filing United States Patent Number (None) Issue Date (None)
Contact OTC	Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org